A recent Device study reported the effectiveness of an ingestible vitals-monitoring pill (VM pill) to monitor vital signs, including heart and respiratory rate based on a human trial.
‘Imitation is best form of flattery’: Regeneron CEO comments on Amgen’s Eylea biosimilar
Regeneron might be ready for competition with its blockbuster drug Eylea, but it’s not clear that investors are. On Thursday morning, the biotech’s leadership fielded